Keros Therapeutics, a Phase 1 biotech developing therapies for blood and musculoskeletal disorders, announced terms for its IPO on Wednesday.
The Lexington, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Keros Therapeutics would command a fully diluted market value of $290 million.
Keros Therapeutics was founded in 2015 and booked $10 million in collaboration revenue for the 12 months ended December 31, 2019. It plans to list on the Nasdaq under the symbol KROS. Jefferies, SVB Leerink and Piper Sandler are the joint bookrunners on the deal. It is expected to price during the week of April 6, 2020.
